E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild to moderate allergic asthma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate safety and tolerability of omalizumab in mild and moderate asthmatics with baseline IgE/body-weight combinations above those defined in the SmPC table. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the pharmacokinetic/pharmacodynamic profile of multiple administration of omalizumab to mild/moderate allergic asthma patients with baseline IgE/body-weight combinations above those defined in the extended dosing table (Table 1-1)
- To determine the pre-dose specific IgE levels in these patients
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must meet the following criteria during the Screening visit and at Baseline evaluations in order to be eligible for the study:
• Diagnosis of allergic asthma ≥ 1 year duration at screening and a history consistent with GINA step 2 or 3 clinical features.
• Eligible Baseline serum IgE value and body-weight combinations:
• Body weight (kg) •Baseline serum IgE (IU/mL) • >40 – 50 • >900 – 2000 • >50 – 60 • >700 – 2000 • >60 – 70 • >600 – 2000 • >70 – 80 • >500 – 2000 • >80 – 90 • >500 – 2000 • >90 – 125 • >300 – 2000 • >125 – 150 • >300 – 2000
• Able to give signed informed consent
• Male or female, 18–55 years old
• For women of childbearing potential, a negative serum pregnancy test within 13 days and a negative urine pregnancy test within 24 hours of study drug administration, and all study drug administrations; women of childbearing potential had to either have been surgically sterilized or, in the opinion of the investigator, be using an effective method of contraception
• Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation
When 11 patients have been included in the 1200 mg group, additional patients to be included into the 1200 mg group have to have IgE levels ≥ 900 IU/mL. |
|
E.4 | Principal exclusion criteria |
Patients meeting any of the following criteria will be excluded from entry into or continuation in the study unless sponsor approval is obtained:
• Documented medical history of anaphylaxis
• Lung disease other than mild to moderate allergic asthma, e.g. COPD
• Use of inhaled tobacco products within the last 12 months
• History of smoking tobacco products of greater than or equal to “10 pack years”
• History of significant medical illnesses other than mild/moderate allergic asthma, including diabetes mellitus, ischemic heart disease, cardiomyopathies, serious neurologic, gastroenterologic, or dermatologic disease, or chronic bronchitis
• Use of oral corticosteroids 3 months prior to Day 1
• Use of any monoclonal antibody in the 6 months before Day 1
• Use of any investigational small molecule drug in the 3 months before Day 1
• Respiratory tract infection in the 4 weeks before Day 1
• History of asthma attack requiring a visit to an emergency room in the 6 weeks before or during Screening
• History of asthma attack requiring treatment with intubation and mechanical ventilation in the 12 months before Day 1
• Evidence for ischemic heart disease or arrhythmia on Screening electrocardiogram (patients not excluded for occasional premature atrial or ventricular contractions)
• Female subjects of child bearing potential who are pregnant, breast feeding or who are either not surgically sterile or are sexually active and not using an acceptable form of contraception as either an hormonal contraceptive since at least two months or the doublebarrier method, i.e. cervical diaphragm with spermicide and condom for the male partner. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and tolerability of omalizumab |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 4 |